Genscript Biotech Sustainability Profile
Genscript Biotech Corporation, commonly referred to as Genscript, is a leading biotechnology company headquartered in the United States. Founded in 2002, Genscript has established itself as a pioneer in the fields of gene synthesis, peptide synthesis, and antibody development, serving a diverse range of industries including pharmaceuticals, academia, and diagnostics. With major operational regions across North America, Europe, and Asia, Genscript offers a comprehensive suite of services that includes custom gene and protein production, CRISPR gene editing, and molecular biology tools. The company is renowned for its innovative approach and high-quality products, which have positioned it as a trusted partner in the global biotech landscape. Genscript's commitment to advancing scientific research has led to numerous accolades, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Genscript Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech's score of 34 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genscript Biotech's reported carbon emissions
In 2024, GenScript Biotech reported total carbon emissions of approximately 39376800 kg CO2e for Scope 1, 114034820 kg CO2e for Scope 2 (market-based), and 387589810 kg CO2e for Scope 3. The combined total for Scope 1 and 2 emissions (market-based) was about 153411610 kg CO2e. In 2023, the company recorded emissions of about 48821780 kg CO2e for Scope 1, 83758360 kg CO2e for Scope 2, and 314658760 kg CO2e for Scope 3, with a total of approximately 132580140 kg CO2e for Scope 1 and 2 combined (market-based). Despite these figures, GenScript Biotech has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company operates independently without cascading emissions data from a parent organisation, maintaining its own reporting standards. Overall, while GenScript Biotech has disclosed significant emissions data across all scopes, it currently lacks formal climate commitments or reduction strategies to mitigate its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 48,821,780 | 00,000,000 |
| Scope 2 | 83,758,360 | 000,000,000 |
| Scope 3 | 314,658,760 | 000,000,000 |
How Carbon Intensive is Genscript Biotech's Industry?
How Carbon Intensive is Genscript Biotech's Location?
Genscript Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genscript Biotech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
